May 11, 2020 Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
April 20, 2020 Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
February 18, 2020 Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
January 22, 2020 Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020
December 9, 2019 Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
November 12, 2019 Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 6, 2019 Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting
October 24, 2019 Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma